From:Elliott, RobinTo:kbarwis@bristolhospital.orgCc:rwisner@bristolhospital.org; alamptey@bristolhospital.orgSubject:Renewal of U.S. NRC License No. 06-02057-01, MCN 584929Date:Thursday, January 08, 2015 9:21:00 AM

 Docket No.
 03001249

 License No.
 06-02057-01

 Control No.
 584929

Kurt Barwis President/CEO Bristol Hospital, Inc. P. O. Box 977 Bristol, CT 06011-0977

SUBJECT: BRISTOL HOSPITAL, INC. , REQUEST FOR ADDITIONAL INFORMATION CONCERNING APPLICATION FOR AMENDMENT TO LICENSE, CONTROL NO. 584929

Dear Mr. Barwis:

Please acknowledge receipt of this email. This is in reference to your application dated September 29, 2014 requesting to amend Nuclear Regulatory Commission License No. 06-02057-01. In order to continue our review, we need the following additional information:

- Section 8.3, "Address(es) Where Licensed Material Will Be Used or Possessed" of NUREG 1556 Vol. 9 Rev 2 discusses requirements for listing the location of use on NRC licenses. In item 3 of your application you listed "Same" for the address where material will be used or possessed. The address listed in item 2 is a post office box which is not an acceptable address as outlined in Section 8.3. Please provide a street address or confirm that "the licensee's facilities located at Newell and Brewster Roads, Bristol, Connecticut" is still accurate.
- 2. Section 8.5, "Radioactive Material" of NUREG 1556 Vol. 9 Rev. 2 provides information that applicants should include in their application regarding requested material. Confirm that you do not possess nor intend to possess PET radiopharmaceuticals.
- 3. Section 8.16, "Facility Diagram" of NUREG 1556 Vol. 9 Rev. 2 provides information that applicants should include in their application regarding their facilities. The following information needs to be provided:
 - a. Show room numbers for the use areas if they exist.
 - b. Show or list what exists above and below the use areas.
 - c. Provide information related to the security of the hot lab.
 - d. Drawings and diagrams that provide exact locations of materials or depict specific locations of safety or security equipment should be marked as "Security-related information withhold under 10 CFR 2.390."

- e. Item 9.5 in your application refers to hospitalized patients. Provide a diagram of the facility where the patients will be housed prior to release and include shielding information that demonstrates compliance with 10 CFR Part 20.1301.
- 4. Section 8.17, "Radiation Monitoring Instruments" of NUREG 1556 Vol. 9 Rev. 2 provides guidance for including the information required in applications for monitoring equipment. It was noted that you previously committed to having a NaI probe on hand for use during permanent implant brachytherapy procedures to assist with monitoring for seeds. (July 2, 2009 letter) It was not included on the list of survey meters in your current application. Confirm that you will have a NaI probe available for this purpose.
- Section 8.20, "Other Equipment and Facilities" of NUREG 1556 Vol. 9 Rev. 2 provides information about specialized requirements for applicants requesting specialized uses. Provide a description of the emergency response equipment available in your manual brachytherapy facility.
- 6. Section 8.25, "Safe Use of Unsealed Licensed Material" of NUREG 1556 Vol. 9 Rev. 2 provides the commitment that applicants must provide in their applications. Provide the following commitment: "We have developed and will implement and maintain procedures for safe use of unsealed byproduct material that meet the requirements of 10 CFR 20.1101 and 10 CFR 20.1301."

Current NRC regulations and guidance are included on the NRC's website at <u>www.nrc.gov</u>; select **Nuclear Materials; Med, Ind, & Academic Uses;** then **Licensee Toolkits, see our toolkit index page.** You may also obtain these documents by contacting the Government Printing Office (GPO) toll-free at 1-866-512-1800. The GPO is open from 8:00 a.m. to 5:30 p.m. EST, Monday through Friday (except Federal holidays).

We will continue our review upon receipt of this information. Please reply to my attention at the Region I Office and refer to Mail Control No. 584929. If you have any technical questions regarding this deficiency letter, please call me at (610) 337-5076.

In order for us to continue a prompt review we request a reply from you within 30 calendar days from the date of this email.

Sincerely,

Robin Q. Elliott Health Physicist U. S. Nuclear Regulatory Commission Region I, Division of Nuclear Materials Safety 2100 Renaissance Blvd King of Prussia, PA 19406-2713 (610) 337-5076 voice (610) 337-5269 fax

Robin.Elliott@nrc.gov